Oppenheimer Reiterates Perform Rating on Amarin Following AMR-102 Study

In a report published Friday, Oppenheimer analyst Akiva Felt reiterated a Perform rating and $8.00 price target on Amarin AMRN.

In the report, Oppenheimer noted, “Amarin reported that the Phase 1 study of AMR-102 (fixed-dose combination of Vascepa+rosuvastatin) demonstrated positive pharmacokinetic and safety results. Specifically, the AMR-102 combination product was absorbed in the same manner as taking the two drugs independently. These findings should not be surprising, in our view, given the drug-drug-interaction (DDI) studies conducted as part of Vascepa's NDA which demonstrated that Vascepa did not inhibit the metabolism of statins. That said, we view the Phase 1 results to be incrementally positive, demonstrating that AMR-102 is formulated in a viable manner. Our focus remains on Vascepa as the key driver for AMRN shares. Reiterate Perform.”

Amarin closed on Thursday at $6.30.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorReiterationAnalyst RatingsAkiva FeltOppenheimer
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!